VC-based PhaseBio sets IPO pricing terms
PhaseBio Pharmaceuticals Inc, a developer of new treatments for orphan diseases, has priced its IPO Of 5 million shares between $12 and $14 per share. PhaseBio will trade the stock on the NASDAQ under the ticker symbol “PHAS.” Citigroup, Cowen and Stifel are the lead underwriters. PhaseBio's backers include Rock Springs Capital, Johnson & Johnson Innovation - JJDC, Mountain Group Capital, Cormorant Asset Management, Hatteras Venture Partners and New Enterprise Associates, according to Crunchbase.
8 October 2018•2 mins read
